...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes care >Aggressive Lipid Lowering Does Not Improve Endothelial Function in Type 2 Diabetes: The Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
【24h】

Aggressive Lipid Lowering Does Not Improve Endothelial Function in Type 2 Diabetes: The Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.

机译：积极降低血脂并不能改善2型糖尿病的内皮功能：糖尿病阿托伐他汀脂质干预（DALI）研究：一项随机，双盲，安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE-Endothelial dysfunction is considered an important early marker of atherosclerosis and cardiovascular risk and is currently used as a surrogate end point for cardiovascular risk in clinical trials. Type 2 diabetic patients show a characteristic dyslipidemia. Aggressive lipid lowering might be an effective method to improve endothelial function in these patients. RESEARCH DESIGN AND METHODS-A randomized, double-blind, placebo-controlled trial was completed to study the effect of 30 weeks' administration of atorvastatin 10 mg and 80 mg on endothelial function, as assessed by B-mode ultrasound of the brachial artery, in 133 patients with type 2 diabetes without a history of cardiovascular disease. RESULTS-Patients with diabetes and diabetic dyslipidemia had considerable endothelium-dependent and endothelium-independent dysfunction; mean flow-mediated vasodilation (SD) was 3.16% (3.56), and mean response on sublingual nitroglycerin was 6.58% (6.04). Despite substantial lowering of all atherogenic lipid parameters, no improvement of endothelium-dependent vasodilatation was found (P > 0.8). CONCLUSIONS-We observed considerable baseline endothelium-dependent and endothelium-independent dysfunction in patients with diabetes and diabetic dyslipidemia without a history of cardiovascular disease. Aggressive lipid lowering by administration of atorvastatin, resulting in substantial improvement of the lipid profile, did not reverse endothelial dysfunction.
机译：目的-内皮功能障碍被认为是动脉粥样硬化和心血管疾病风险的重要早期标志，目前在临床试验中被用作心血管疾病风险的替代终点。 2型糖尿病患者表现出典型的血脂异常。积极降低脂质可能是改善这些患者内皮功能的有效方法。研究设计和方法-一项随机，双盲，安慰剂对照试验已完成，研究通过肱动脉B型超声检查，分别服用30mg 10mg和80mg阿托伐他汀对血管内皮功能的影响， 133例无心血管疾病史的2型糖尿病患者中。结果：患有糖尿病和糖尿病血脂异常的患者具有相当大的内皮依赖性和非内皮依赖性功能障碍。平均流量介导的血管舒张（SD）为3.16％（3.56），舌下硝化甘油的平均响应为6.58％（6.04）。尽管所有动脉粥样硬化性脂质参数均显着降低，但未发现内皮依赖性血管舒张功能的改善（P> 0.8）。结论-我们在没有心血管疾病史的糖尿病和糖尿病血脂异常患者中观察到相当大的基线内皮依赖性和内皮依赖性功能障碍。服用阿托伐他汀可降低血脂，导致血脂水平显着改善，但并未逆转内皮功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号